IMPACT BIOMEDICAL INC. (IBO) SEC Filings & Earnings Calls
EquiReason read 6 IMPACT BIOMEDICAL INC. SEC filings in the last 12 months. Latest: 8-K on 2026-09-17 — Impact Biomedical Inc. announces filing of Form F-4 registration statement for proposed merger with Zoar Limited. Transaction is a business combination creating a pharmaceutical co.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 30.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 6 Nov, in 13 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
17 Sep 20268-K · 7.01Impact Biomedical Inc. announces filing of Form F-4 registration statement for proposed merger with Zoar Limited. Transaction is a business combination creating a pharmaceutical company focused on APIs.being acquiredopen
Risks flagged
Transaction subject to multiple conditions including SEC effectiveness, stockholder approval, and NYSE American listing approval
“completion subject to Registration Statement being declared effective, approval by Impact stockholders, approval of listing on NYSE American”
15 Sep 20268-K · 7.01Reverse stock split 1-for-12.62 to regain NYSE American listing compliance and facilitate merger with Zoar Limited; shares to drop from ~107.8M to ~8.5M.open
Figures in the filing · each found in the filing text
| Shares outstanding (pre-split) · 2026-09-14 | 107,821,231 |
Risks flagged
Reverse stock split and merger uncertainty; no assurance of continued listing or deal completion.
“No assurance can be given that the Reverse Stock Split will enable the Company to maintain compliance with applicable listing standards or that the proposed merger will be consummated.” · word for word
7 Aug 202610-QQuarterly revenue declined 57% QoQ; net loss improved due to prior-year non-cash items.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $3000.00 | -57% y/y |
| Net loss · Q2-2026 | $-700000.00 | -95% y/y |
| Operating cash flow · H1-2026 | $6000.00 | -100% y/y |
Risks flagged
Going concern risk
“These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued.” · word for word
Revenue concentration and decline
“Biotech retail sales $ 3,000 $ 7,000 -57 %” · word for word
12 May 202610-QImpact Biomedical reported Q1 2026 results with net loss of $2.3 million, increased 79% YoY, and raised going concern doubt.earningsopen
Figures in the filing · each found in the filing text
| Net loss · Q1-2026 | $-2M | +79% y/y |
| Revenue · Q1-2026 | $7000.00 | |
| Net cash used in operating activities · Q1-2026 | $-464000.00 | -32% y/y |
Risks flagged
Going concern uncertainty
“These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued.” · word for word
Dependence on related-party financing
“Net cash provided by financing activities was $482,000 for the three months ended March 31, 2026 and represents borrowings from a DSS, a related party.” · word for word
11 Mar 202610-KAnnual report filing with no material event.open
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $32000.00 | |
| Net loss · FY2025 | $-12M | -52% y/y |
| Operating cash flow · FY2025 | $-2M | -34% y/y |
Risks flagged
Going concern risk
“As reflected in the accompanying financial statements the Company has incurred operating losses as well as negative cash flows from operating activities over the past two years. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued.” · word for word
7 Nov 202510-QImpact Biomedical reported a net loss of $1.475 million for Q3 2025 compared to net income of $4.241 million in Q3 2024, with substantial doubt about going concern.earningsopen
Figures in the filing · each found in the filing text
| Net loss · Q3-2025 | $-1M | -135% y/y |
| Operating cash flow · 9M-2025 | $-2M | -25% y/y |
Risks flagged
Going concern uncertainty
“These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued.” · word for word
IMPACT BIOMEDICAL INC. — questions
- What did IMPACT BIOMEDICAL INC. file recently?
- 6 SEC filings in the last 12 months. Latest: 8-K on 2026-09-17 — Impact Biomedical Inc. announces filing of Form F-4 registration statement for proposed merger with Zoar Limited. Transaction is a business combination creating a pharmaceutical company focused on APIs.
Every figure on this page comes from IMPACT BIOMEDICAL INC.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.